Sanofi, Formation Bio, and OpenAI have joined forces to create Muse, an artificial intelligence (AI) tool aimed at significantly reducing the time required for clinical trial recruitment and content development. The collaboration seeks to address critical bottlenecks in pharmaceutical research and development, potentially accelerating the availability of new therapies.
Muse is designed to streamline several key aspects of clinical trial preparation. It begins by compiling comprehensive research on diseases, patient demographics, and the existing therapeutic landscape. The AI then analyzes this information to pinpoint ideal patient profiles and formulate recruitment strategies that emphasize diverse populations. A key feature of Muse is its ability to automatically generate recruitment materials and prescreening questionnaires, customized for specific patient subgroups and translated into multiple languages and styles. The tool also incorporates regulatory guidelines to ensure the production of high-quality, compliant materials. Data privacy is a core consideration throughout Muse's deployment.
Sanofi and Formation Bio intend to integrate Muse into upcoming clinical trials, with an initial focus on Phase 3 trials for Sanofi's multiple sclerosis treatments. By automating and accelerating the recruitment process, the collaboration hopes to enhance the efficiency and inclusivity of clinical trials, ultimately benefiting patients and advancing medical science.
